Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.

In an effort to develop dual PPARalpha/gamma activators with improved therapeutic efficacy, a series of diaryl alpha-ethoxy propanoic acid compounds comprising two aryl groups linked by rigid oxime ether or isoxazoline ring were designed and synthesized and their biological activities were examined. Most of the compounds possessing an oxime ether linker were more potent PPARgamma activators than the lead PPARalpha/gamma dual agonist, tesaglitazar in vitro. Compound 18, one of the derivatives with an oxime ether linker, was found to selectively transactivate PPARgamma (EC 50 = 0.028 microM) over PPARalpha (EC 50 = 7.22 microM) in vitro and lower blood glucose in db/ db mice more than muraglitazar after oral treatment for 11 days.

[1]  B. Fagerberg,et al.  Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance , 2008 .

[2]  Hyun-Ju Park,et al.  Design, synthesis, and structure–activity relationship of carbamate-tethered aryl propanoic acids as novel PPARα/γ dual agonists , 2007 .

[3]  S. Roy,et al.  Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or oedema? , 2007 .

[4]  Hans Peter Märki,et al.  Structure-based design of indole propionic acids as novel PPARα/γ co-agonists , 2006 .

[5]  Z. Shen,et al.  Synthesis and evaluation of azaindole-α-alkyloxyphenylpropionic acid analogues as PPARα/γ agonists , 2006 .

[6]  E. Topol,et al.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.

[7]  S. Cohen.  Effects of PPARγ and Combined Agonists on the Urinary Tract of Rats and Other Species , 2005 .

[8]  L. Iversen,et al.  Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo , 2005, Toxicologic pathology.

[9]  A. Bross,et al.  Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice , 2005, International Journal of Obesity.

[10]  Jong-Wha Jung,et al.  Concise syntheses of (+)-macrosphelides A and B. , 2005, Organic letters.

[11]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[12]  Weiqi Wang,et al.  Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. , 2005, Journal of medicinal chemistry.

[13]  J. Berger,et al.  Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia. , 2005, Journal of medicinal chemistry.

[14]  B. P. Kota,et al.  An overview on biological mechanisms of PPARs. , 2005, Pharmacological research.

[15]  D. Savage.  PPARγ as a metabolic regulator: insights from genomics and pharmacology , 2005, Expert Reviews in Molecular Medicine.

[16]  L. Iversen,et al.  Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[17]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[18]  J. Fleckner,et al.  Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. , 2003, Journal of medicinal chemistry.

[19]  가사이순지,et al.  Carboxylic acid derivatives and salt thereof , 2002 .

[20]  H. Lebovitz,et al.  Differentiating members of the thiazolidinedione class: a focus on safety , 2002, Diabetes/metabolism research and reviews.

[21]  Ingrid Pettersson,et al.  Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity , 2002 .

[22]  T. Willson,et al.  The PPARs: From Orphan Receptors to Drug Discovery , 2000 .

[23]  O. Mitsunobu,et al.  Preparation of Esters of Phosphoric Acid by the Reaction of Trivalent Phosphorus Compounds with Diethyl Azodicarboxylate in the Presence of Alcohols , 1967 .

[24]  M. Hawthorne,et al.  A Re-examination of the Peroxyacid Cleavage of Ketones. I. Relative Migratory Aptitudes , 1958 .

[25]  R. Buckingham,et al.  Thiazolidinediones and their Fluid-Related Adverse Effects , 2007, Drug safety.

[26]  J. Leahy.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial , 2007 .

[27]  S. Manfredini,et al.  Ring Cleavage of 3,5-Disubstituted 2-lsoxazolines by Molybdenum Hexacarbonyl and Water to ß-Hydroxy Ketones , 1987 .